喘息・COPD (慢性閉塞性肺疾患) 治療薬の世界市場の予測：2019年～2029年

世界の喘息・COPD (慢性閉塞性肺疾患) 治療薬市場は、2018年に320億米ドルに達し、2019年～2024年のCAGR (複合年間成長率) で、6.0％の成長が予測されています。

当レポートでは、世界の喘息・COPD (慢性閉塞性肺疾患) 治療薬市場について調査分析し、世界市場の予測と分析、地域別市場の予測・促進要因・抑制要因、主要企業などについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 喘息・COPD治療薬のイントロダクション

• 製薬業：概要
• 呼吸器疾患の分類
• 喘息とは
• COPD (慢性閉塞性肺疾患) とは
• 喘息・COPD治療における主な薬剤分類
• 治験の段階
• 調査範囲

第3章 喘息・COPD治療薬：世界市場

• 世界の呼吸器系医薬品市場：治療分野別
• 世界の喘息・COPD治療薬市場
• 売上予測：治療分野別
• 売上予測：薬剤分類別
• 配合剤が市場でリード
• セグメントシェアの変動
• 動向と発展

第4章 気管支拡張剤単剤療法市場

第5章 抗炎症薬市場

第6章 配合剤市場

第7章 主要国市場

• 地域別の内訳
• 地域別の予測
• 米国
• 日本
• EU5ヶ国
• BRIC諸国
• メキシコ

第8章 喘息・COPD治療薬市場における主要企業

• 競争激化
• 主要企業
• 主要企業：市場予測
• 市場シェアの変動
• GSK
• Boehringer Ingelheim
• AstraZeneca
• Merck & Co.(Merck)
• Novartis
• Roche
• Teva

第9章 喘息・COPD治療薬パイプライン分析

第10章 喘息・COPD治療薬市場の定性分析

• SWOT分析
• ファイブフォース分析

第11章 結論

List of Tables

• Table 2.1 Classification of Respiratory Diseases, 2018
• Table 2.2 Causes of Asthma, 2018
• Table 2.3 Triggers of Asthma, 2018
• Table 2.4 Clinical Trial Phases
• Table 3.1 Global Asthma & COPD Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2018
• Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m) and Market Shares (%), 2017
• Table 3.3 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 3.6 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029
• Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2018, 2023 and 2029
• Table 4.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2018
• Table 4.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2017
• Table 4.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029
• Table 4.4 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2017
• Table 4.5 Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
• Table 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2018, 2023 and 2029
• Table 4.7 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.8 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.9 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.10 Leading SABAs in 2017
• Table 4.11 SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
• Table 4.12 SABAs Market: Market Shares (%) by Drug, 2017, 2023 and 2029
• Table 4.13 GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.14 Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.15 Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.16 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.17 Leading LABAs: Revenues ($m) and Market Shares (%), 2017
• Table 4.18 LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
• Table 4.19 Leading LABAs: Market Shares (%) by Drug, 2017, 2023 and 2029
• Table 4.20 Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.21 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.22 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 4.23 GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2017
• Table 5.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2017
• Table 5.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029
• Table 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2023 and 2029
• Table 5.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2017
• Table 5.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
• Table 5.7 Corticosteroids Market: Market Share (%) by Drug, 2017, 2023 and 2029
• Table 5.8 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2017-2029
• Table 5.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.10 Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.11 Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2017
• Table 5.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
• Table 5.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2017, 2023 and 2029
• Table 5.15 Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
• Table 5.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2017, 2023 and 2029
• Table 5.18 Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.19 Teva: Cinquil/Cinquair Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.20 GSK: Nucala Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.22 Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 5.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 6.1 Leading Combination Drugs: Revenues ($m) and Market Share (%), 2017
• Table 6.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
• Table 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2017, 2023 and 2029
• Table 6.4 GSK: Advair/Seretide Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 6.5 AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 6.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 6.7 Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 6.8 GSK: Relvar/Breo Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.1 Global Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2017
• Table 7.2 Global Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2017-2029
• Table 7.3 Leading Regional Asthma and COPD Therapies Market: Market Share (%) 2018, 2023 and 2029
• Table 7.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2018
• Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029
• Table 7.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2018, 2023 and 2029
• Table 7.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029
• Table 7.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
• Table 7.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029
• Table 7.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 7.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
• Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2017
• Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
• Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2017, 2023 and 2029
• Table 8.4 GSK: Overview
• Table 8.5 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
• Table 8.6 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
• Table 8.7 GSK: Asthma and COPD Therapies Pipeline
• Table 8.8 Boehringer Ingelheim: Overview
• Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
• Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
• Table 8.11 AstraZeneca: Overview
• Table 8.12 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
• Table 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
• Table 8.14 AstraZeneca: Asthma and COPD Therapies Pipeline
• Table 8.15 Merck: Overview
• Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
• Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
• Table 8.18 Novartis: Overview
• Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
• Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
• Table 8.21 Novartis: Asthma and COPD Therapies Pipeline
• Table 8.22 Roche: Overview
• Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
• Table 8.24 Teva: Overview
• Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
• Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
• Table 8.27 Teva: Asthma and COPD Therapies Pipeline

List of Figures

• Figure 1.1 Global Asthma and COPD Therapies Market Segmentation Overview, 2018
• Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2018
• Figure 2.2 Summary of GOLD Guidance for COPD Treatment, 2018
• Figure 3.1 World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2018
• Figure 3.2 World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2018
• Figure 3.3 Top 10 Asthma and COPD Therapies: Market Shares (%), 2017
• Figure 3.4 World Asthma and COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 3.5 World Asthma Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 3.6 World COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 3.7 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2018
• Figure 3.8 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2023
• Figure 3.9 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2029
• Figure 3.10 World Asthma and COPD Therapies Market: Drivers and Restraints, 2017-2029
• Figure 4.1 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2018
• Figure 4.2 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2023
• Figure 4.3 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2029
• Figure 4.4 Bronchodilator Monotherapy Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 4.5 Anticholinergics Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2018
• Figure 4.7 Anticholinergics Market: Market Shares (%) by Drug, 2023
• Figure 4.8 Anticholinergics Market: Market Shares (%) by Drug, 2029
• Figure 4.9 Boehringer Ingelheim: Spiriva Revenue ($m) and AGR (%), 2017-2029
• Figure 4.10 Boehringer Ingelheim: Atrovent Revenue ($m) and AGR (%), 2017-2029
• Figure 4.11 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m) and AGR (%), 2017-2029
• Figure 4.12 SABAs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 4.13 SABAs Market: Market Shares (%) by Drug, 2018
• Figure 4.14 SABAs Market: Market Shares (%) by Drug, 2023
• Figure 4.15 SABAs Market: Market Shares (%) by Drug, 2029
• Figure 4.16 GSK: Ventolin Revenue ($m) and AGR (%), 2017-2029
• Figure 4.17 Teva: ProAir Revenue ($m) and AGR (%), 2017-2029
• Figure 4.18 Merck: Proventil Revenue ($m) and AGR (%), 2017-2029
• Figure 4.19 Dainippon Sumitomo: Xopenex Revenue ($m) and AGR (%), 2017-2029
• Figure 4.20 LABAs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 4.21 LABAs Market: Market Shares (%) by Drug, 2018
• Figure 4.22 LABAs Market: Market Shares (%) by Drug, 2023
• Figure 4.23 LABAs Market: Market Shares (%) by Drug, 2029
• Figure 4.24 Merck/Novartis: Foradil Revenue ($m) and AGR (%), 2017-2029
• Figure 4.25 Dainippon Sumitomo: Brovana Revenue ($m) and AGR (%), 2017-2029
• Figure 4.26 Novartis: Arcapta/Onbrez Revenue ($m) and AGR (%), 2017-2029
• Figure 4.27 GSK: Serevent Revenue ($m) and AGR (%), 2017-2029
• Figure 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2017
• Figure 5.2 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2017
• Figure 5.3 Anti-Inflammatory Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2023
• Figure 5.5 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2023
• Figure 5.6 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2029
• Figure 5.7 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2029
• Figure 5.8 Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 5.9 Corticosteroids Market: Market Share (%) by Drug, 2017
• Figure 5.10 Corticosteroids Market: Market Share (%) by Drug, 2023
• Figure 5.11 Corticosteroids Market: Market Share (%) by Drug, 2029
• Figure 5.12 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2017-2029
• Figure 5.13 AstraZeneca: Pulmicort Revenue ($m) and AGR (%), 2017-2029
• Figure 5.14 Teva: QVAR Revenue ($m) and AGR (%), 2017-2029
• Figure 5.15 Merck: Asmanex Revenue ($m) and AGR (%), 2017-2029
• Figure 5.16 Anti-Leukotrienes Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 5.17 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2018
• Figure 5.18 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2023
• Figure 5.19 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2029
• Figure 5.20 Merck: Singulair Revenue ($m) and AGR (%), 2017-2029
• Figure 5.21 Monoclonal Antibodies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 5.22 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2017
• Figure 5.23 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2023
• Figure 5.24 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2029
• Figure 5.25 Novartis/Roche: Xolair Asthma Indication Revenue ($m) and AGR (%), 2017-2029
• Figure 5.26 Teva: Cinquil/Cinquair Revenue ($m) and AGR (%), 2017-2029
• Figure 5.27 GSK: Nucala Revenue ($m) and AGR (%), 2017-2029
• Figure 5.28 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m) and AGR (%), 2017-2029
• Figure 5.29 Roche: Lebrikizumab Revenue ($m) and AGR (%), 2017-2029
• Figure 5.30 Regeneron/Sanofi: Dupilumab Revenue ($m) and AGR (%), 2017-2029
• Figure 6.1 Combination Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
• Figure 6.2 Combination Drugs Market: Market Shares (%) by Drug, 2017
• Figure 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2023
• Figure 6.4 Combination Drugs Market: Market Shares (%) by Drug, 2029
• Figure 6.5 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2017-2029
• Figure 6.6 AstraZeneca: Symbicort Revenue ($m) and AGR (%), 2017-2029
• Figure 6.7 Boehringer Ingelheim: Combivent Revenue ($m) and AGR (%), 2017-2029
• Figure 6.8 Merck: Dulera Revenue ($m) and AGR (%), 2017-2029
• Figure 6.9 GSK: Relvar/Breo Revenue ($m) and AGR (%), 2017-2029
• Figure 7.1 Global Asthma and COPD Therapies Market: Revenues ($m) by Region, 2017
• Figure 7.2 Global Asthma and COPD Therapies Market: Market Shares (%) by Region, 2017
• Figure 7.3 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2017-2029
• Figure 7.4 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2023
• Figure 7.5 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2029
• Figure 7.6 World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2018
• Figure 7.7 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2018
• Figure 7.8 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2023
• Figure 7.9 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2029
• Figure 7.10 US Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 7.11 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 7.12 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2017-2029
• Figure 7.13 German Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 7.14 French Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 7.15 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and 2017-2029
• Figure 7.16 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 7.17 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 7.18 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2017-2029
• Figure 7.19 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 7.20 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 7.21 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
• Figure 7.22 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 7.23 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
• Figure 8.1 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2017
• Figure 8.2 Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2017
• Figure 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2023
• Figure 8.4 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2023
• Figure 8.5 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2029
• Figure 8.6 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2029
• Figure 8.7 GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
• Figure 8.8 GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
• Figure 8.9 GSK: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
• Figure 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
• Figure 8.11 Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
• Figure 8.12 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
• Figure 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
• Figure 8.14 AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
• Figure 8.15 AstraZeneca: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
• Figure 8.16 Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
• Figure 8.17 Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
• Figure 8.18 Merck: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
• Figure 8.19 Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
• Figure 8.20 Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
• Figure 8.21 Novartis: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
• Figure 8.22 Roche: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
• Figure 8.23 Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
• Figure 8.24 Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
• Figure 8.25 Teva: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
• Figure 10.1 Asthma and COPD Therapies Market: Strengths and Weaknesses, 2017-2029
• Figure 10.2 Asthma and COPD Therapies Market: Opportunities and Threats, 2017-20279
• Figure 10.3 Porter's Five Forces Analysis of the Asthma and COPD Therapies Market, 2017-2029
• Figure 12.1 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2017-2029

Companies Listed

• 3M Drug Delivery Systems
• Actavis
• Alcon
• Alembic
• Allen and Hanburys
• Allergan
• Almirall
• Apotex
• Array BioPharma
• Aspen Pharmacare
• Astellas Pharma
• AstraZeneca
• Aurobindo Pharma
• Bayer
• Ben Vue Laboratories
• BioWa
• BioXpress Therapeutics
• Boehringer Ingelheim
• Breath Limited
• Bristol-Meyer Squibbs
• Catalent Pharma Solutions
• Cephalon
• Ception Therapeutics
• Chiesi Farmaceutici
• Ciba-Geigy
• Cipla
• Circassia Pharmaceuticals
• CVS Caremark
• Daewoong Pharmaceutical
• Dainippon Sumimoto
• Dr. Reddy's Laboratories
• Eli Lilly
• Express Scripts
• Forest Laboratories
• Fountain Biopharma
• Genentech (Roche)
• Grifols
• GSK
• Hikma Pharmaceuticals
• Invion
• Kamada
• Kyorin Pharmaceutical
• Kyowa Hakko Kirin
• Medimmune
• Menarini
• Merck & Co.
• Mylan
• Novartis
• Nycomed
• Omega Pharma
• Orion Pharmaceuticals
• Pearl Therapeutics
• Perrigo
• Pfizer
• Prosonix
• Reckitt Becnkiser
• Regeneron
• Roche
• Roxane Laboratories
• Sandoz (Novartis)
• Sanofi
• Schering-Plough
• SkyePharm
• Sofotec
• Sunovion Pharmaceuticals
• Synairgen
• Takeda Pharmaceuticals
• Tanox
• Teva
• Theravance
• UCB
• Vectura
• Viatris
• Watson (Actavis)

Organisations Mentioned in the Report

• American Lung Association
• Bundesministerium fur Gesundheit (German Ministry of Health)
• European Lung Foundation
• European Respiratory Society
• Food and Drug Administration
• Pharmaceuticals and Medical Devices Agency (PMDA)
• The European Federation of Allergy and Airway Diseases (EFA)
• The Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
• University of Michigan Medical School
• World Health Organization (WHO)

The global asthma & COPD therapies market was valued at $32bn in 2018 and is projected to grow at a CAGR of 6.0% in the first half of the forecast period. In 2018, the combination drugs segment held 39% of the global asthma & COPD market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 309-page report you will receive 112 tables and 131 figures - all unavailable elsewhere.

The 309-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Asthma & COPD Therapies Market forecasts from 2019-2029, further broken down into:

Global Asthma Therapies Market forecasts

Global COPD Therapies Market forecasts

Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:

• Bronchodilators monotherapy
• Anti-inflammatory drugs
• Combination drugs

Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:

• Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex

• Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,

• Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris

Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:

• Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex

• Anti-leukotrienes: Singulair

• Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

Revenue forecast for the Combination drugs market and the leading drugs:

• Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo

This report provides individual revenue forecasts from 2019-2029 for these regional and national markets:

• The US
• Japan
• EU5: Germany, France, UK, Italy, Spain
• BRIC: Brazil, Russia, India, China
• Mexico
• Other Countries

This report discusses the leading companies in the global asthma & COPD therapies market:

• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Roche
• Teva

This report discusses drugs currently in clinical development for treating asthma and COPD.

This report discusses the SWOT analysis as well as porter's five forces analysis of the global asthma & COPD therapies market.

Visiongain's study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.

Buy our report today Global Asthma & COPD Therapies Market 2019-2029: Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

• 1.1 Global Asthma and COPD Therapies Market Overview
• 1.2 Global Asthma and COPD Therapies Market Segmentation
• 1.3 Why You Should Read This Report
• 1.4 How This Report Delivers
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report For?
• 1.7 Methodology
• 1.8 Frequently Asked Questions (FAQ)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2. Introduction to Asthma and COPD Therapies

• 2.1 The Pharmaceutical Industry: A Very Brief Overview
• 2.2 Classifying Respiratory Diseases: Obstructive and Restrictive
  • 2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
• 2.3 What is Asthma?
  • 2.3.1 Trends in Asthma Prevalence
  • 2.3.2 Pathophysiology of Asthma
  • 2.3.3 Symptoms of Asthma
  • 2.3.4 Causes and Triggers for Asthma
  • 2.3.5 Treatment of Asthma
  • 2.3.6 Guidelines for Asthma Treatment
  • 2.3.7 Drug Treatments for Asthma
  • 2.3.8 Drug Delivery Methods in Asthma
• 2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
  • 2.4.1 Trends in COPD Prevalence
  • 2.4.2 Pathophysiology of COPD
  • 2.4.3 Signs and Symptoms of COPD
  • 2.4.4 Treatment of COPD
  • 2.4.5 Drug Treatments for COPD
  • 2.4.6 Guidelines for COPD Treatment
• 2.5 Major Drug Classes in the Treatment of Asthma and COPD
  • 2.5.1 Bronchodilators
    • 2.5.1.1 Beta2-Agonists
    • 2.5.1.2 Anticholinergics
  • 2.5.2 Anti-Inflammatory Drugs
    • 2.5.2.1 Corticosteroids
    • 2.5.2.2 Leukotriene Receptor Antagonists
    • 2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
  • 2.5.3 Combination Drugs
• 2.6 Phases of Clinical Trials
• 2.7 Scope of this Report

3. Asthma and COPD Therapies: Global Market 2019-2029

• 3.1 The Global Respiratory Drugs Market by Therapeutic Area
• 3.2 The Global Asthma and COPD Therapies Market in 2018
  • 3.2.1 Leading Asthma and COPD Therapies
  • 3.2.2 Leading Companies in the Asthma and COPD Therapies Market
• 3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2017-2029
  • 3.3.1 Global Asthma Therapies Market: Sales Forecast, 2017-2029
  • 3.3.2 Global COPD Therapies Market: Sales Forecast 2017-2029
• 3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2017-2029
• 3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
• 3.6 How Will Segmental Shares Change to 2029
  • 3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2017-2029
• 3.7 Asthma and COPD Therapies: Trends and Developments
  • 3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
  • 3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?

4. Bronchodilator Monotherapy Market 2019-2029

• 4.1 Introduction to Bronchodilator Monotherapy
• 4.2 The Bronchodilator Monotherapy Market in 2017
  • 4.2.1 Leading Bronchodilators in 2017
  • 4.2.2 Bronchodilator Monotherapy: Market Forecast 2019-2029
  • 4.2.3 How Will Market Shares by Drug Class Change to 2029?
• 4.3 The Anticholinergics Market 2019-2029
  • 4.3.1 Leading Anticholinergics in 2017
  • 4.3.2 Anticholinergics: Market Forecast 2019-2029
  • 4.3.3 Market Share of Leading Anticholinergics to 2029
  • 4.3.4 Spiriva (tiotropium - Boehringer Ingelheim)
    • 4.3.4.1 Spiriva: Sales Forecast 2019-2029
    • 4.3.4.2 Spiriva: Recent Developments
  • 4.3.5 Atrovent (ipratropium, Boehringer Ingelheim)
    • 4.3.5.1 Atrovent: Sales Forecast 2019-2029
  • 4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini)
    • 4.3.6.1 Eklira/Tudorza/Bretaris: Sales Forecast 2017-2029
• 4.4 The SABAs Market 2019-2029
  • 4.4.1 Leading SABAs in 2017
  • 4.4.2 SABAs: Market Forecast 2019-2029
  • 4.4.3 Market Share of Leading SABAs to 2029
  • 4.4.4 Ventolin (salbutamol, GSK)
    • 4.4.4.1 Ventolin: Sales Forecast 2019-2029
  • 4.4.5 ProAir (salbutamol, Teva)
    • 4.4.5.1 ProAir: Sales Forecast 2019-2029
  • 4.4.6 Proventil (salbutamol, Merck)
    • 4.4.6.1 Proventil: Sales Forecast 2019-2029
  • 4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
    • 4.4.7.1 Xopenex: Sales Forecast 2019-2029
• 4.5 The Long-Acting Beta2-Agonist (LABA) Market 2017-2029
  • 4.5.1 Leading LABAs in 2017
  • 4.5.2 LABAs: Market Forecast 2019-2029
  • 4.5.3 Market Share of Leading LABAs to 2029
  • 4.5.4 Foradil (formoterol, Merck/Novartis)
    • 4.5.4.1 Foradil: Sales Forecast 2017-2029
  • 4.5.5 Brovana (arfomoterol, Dainippon Sumitomo)
    • 4.5.5.1 Brovana: Sales Forecast 2017-2029
  • 4.5.6 Arcapta/Onbrez (indacaterol, Novartis)
    • 4.5.6.1 Arcapta/Onbrez: Sales Forecast 2017-2029
  • 4.5.7 Serevent (salmeterol, GSK)
    • 4.5.7.1 Serevent: Sales Forecast 2017-2029

5. Anti-inflammatory Drugs Market 2019-2029

• 5.1 Introduction to Anti-Inflammatory Drugs
• 5.2 The Anti-Inflammatory Drugs Market in 2017
  • 5.2.1 Leading Anti-Inflammatory Drugs in 2017
  • 5.2.2 Anti-Inflammatory Drugs: Market Forecast 2019-2029
  • 5.2.3 How Will Market Shares by Drug Class Change to 2029?
• 5.3 The Corticosteroids Market 2019-2029
  • 5.3.1 Leading Corticosteroids in 2017
  • 5.3.2 Corticosteroids: Market Forecast 2019-2029
  • 5.3.3 Market Share of Leading Corticosteroids to 2029
  • 5.3.4 Flixotide/Flovent (fluticasone propionate, GSK)
    • 5.3.4.1 Flixotide/Flovent: Sales Forecast 2019-2029
  • 5.3.5 Pulmicort (budesonide, AstraZeneca)
    • 5.3.5.1 Pulmicort: Sales Forecast 2019-2029
  • 5.3.6 QVAR (beclometasone, Teva)
    • 5.3.6.1 QVAR: Sales Forecast 2017-2029
  • 5.3.7 Asmanex (mometasone, Merck)
    • 5.3.7.1 Asmanex: Sales Forecast 2019-2029
• 5.4 The Anti-Leukotrienes Market 2019-2029
  • 5.4.1 Leading Anti-Leukotrienes in 2017
  • 5.4.2 Anti-Leukotrienes: Market Forecast 2019-2029
  • 5.4.3 Market Share of Leading Anti-Leukotrienes to 2029
  • 5.4.4 Singulair (montelukast, Merck)
    • 5.4.4.1 Singulair: Sales Forecast 2017-2029
• 5.5 The Monoclonal Antibodies Market 2019-2029
  • 5.5.1 Monoclonal Antibodies: Market Forecast 2019-2029
  • 5.5.2 Market Share of Leading Monoclonal Antibodies to 2029
  • 5.5.3 Xolair (omalizumab, Novartis/Roche)
    • 5.5.3.1 Xolair: Sales Forecast 2019-2029
  • 5.5.4 Cinquil/Cinquair (reslizumab, Teva)
    • 5.5.4.1 Cinquil: Sales Forecast 2019-2029
  • 5.5.5 Nucala (Mepolizumab, GSK)
    • 5.5.5.1 Nucala: Sales Forecast 2019-2029
  • 5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
    • 5.5.6.1 Benralizumab: Sales Forecast 2019-2029
  • 5.5.7 Lebrikizumab (RG3637, Roche)
    • 5.5.7.1 Lebrikizumab: Sales Forecast 2019-2029
  • 5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)
    • 5.5.8.1 Dupilumab: Sales Forecast 2017-2029

6. Combination Drugs Market 2019-2029

• 6.1 Introduction to Combination Drugs
  • 6.1.1 Leading Combination Drugs in 2017
  • 6.1.2 Combination Drugs: Market Forecast 2017-2029
  • 6.1.3 How Will Market Shares by Drug Change to 2029?
  • 6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK)
    • 6.1.4.1 Advair/Seretide: Sales Forecast 2017-2029
  • 6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
    • 6.1.5.1 Symbicort: Sales Forecast 2017-2029
    • 6.1.5.2 Symbicort: The SMART Concept
  • 6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
    • 6.1.6.1 Combivent: Sales Forecast 2017-2029
  • 6.1.7 Dulera (formoterol/mometasone, Merck)
    • 6.1.7.1 Dulera: Sales Forecast 2017-2029
  • 6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
    • 6.1.8.1 Breo/Relvar: Sales Forecast 2017-2029
• 6.2 Recently Launched Combination Drugs

7. Leading National Markets 2017-2029

• 7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market
• 7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2017-2029
  • 7.2.1 How Will Regional Market Shares Change to 2029?
  • 7.2.2 National Breakdown of the Global Asthma and COPD Therapies Market
  • 7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2017-2029
  • 7.2.4 How Will National Market Shares Change to 2029?
• 7.3 The US Asthma and COPD Therapies Market 2017-2029
  • 7.3.1 The US Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.3.2 US Asthma and COPD Therapies Market Trends and Developments
    • 7.3.2.1 Increasing COPD Prevalence in the US
    • 7.3.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
    • 7.3.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
• 7.4 Japanese Asthma and COPD Therapies Market 2017-2029
  • 7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
    • 7.4.2.1 Is Generic Penetration to Reach 60% by 2018?
    • 7.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform
• 7.5 EU5 Asthma and COPD Therapies Market 2017-2029
  • 7.5.1 German Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.5.2 French Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.5.3 UK Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.5.4 Italian Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
    • 7.5.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
    • 7.5.6.2 France: Social Security Finance Bill 2015
    • 7.5.6.3 UK: Improving Asthma and COPD Patient Outcomes
    • 7.5.6.4 Italy: Austerity Measures Limiting Growth
    • 7.5.6.5 Spain: The Start of Recovery in the Spanish Economy
• 7.6 BRIC Asthma and COPD Therapies Market 2017-2029
  • 7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
    • 7.6.2.1 China's Industrial Future and Asthma/COPD
    • 7.6.2.2 Expansion of Healthcare Coverage and Reimbursement
    • 7.6.2.3 Price Controls and the Anhui Model
  • 7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
    • 7.6.4.1 Increasing Access to Medicines
  • 7.6.5 Indian Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments
    • 7.6.6.1 Drug Prices Control Order 2013
    • 7.6.6.2 Expansion of Healthcare Provision
  • 7.6.7 Russian Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments
    • 7.6.8.1 No Embargo on Foreign Drug Imports
    • 7.6.8.2 Pharma2021 and the Russian Pharmaceutical Industry
• 7.7 Mexican Asthma and COPD Therapies Market 2017-2029
  • 7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2017-2029
  • 7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
    • 7.7.2.1 Seguro Popular: Mexican Healthcare Reform
    • 7.7.2.2 COFEPRIS: Regulatory Changes and Improvements
    • 7.7.2.3 Mexico's Agreement for Innovation

8. Leading Companies in the Asthma and COPD Therapies Market

• 8.1 Asthma and COPD Therapies: Increasing Competition
• 8.2 Leading Companies in Asthma and COPD in 2017
• 8.3 Leading Companies: Market Forecast 2017-2029
• 8.4 How Will Leading Companies' Market Shares Change to 2029?
• 8.5 GSK
  • 8.5.1 GSK: Asthma and COPD Therapies
  • 8.5.2 GSK: Sales Forecast 2017-2029
  • 8.5.3 GSK: Products in Development
  • 8.5.4 GSK: Recent Developments
    • 8.5.4.1 Recently Launched Combination Drugs
    • 8.5.4.2 GSK Divests OTC Products
    • 8.5.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
    • 8.5.4.4 GSK Presents Data on Eosinophil Levels and COPD
• 8.6 Boehringer Ingelheim
  • 8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies
  • 8.6.2 Boehringer Ingelheim: Sales Forecast 2017-2029
  • 8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
  • 8.6.4 Boehringer Ingelheim: Recent Developments
    • 8.6.4.1 Expansion of Respimat Manufacturing Capacity
    • 8.6.4.2 Respimat Safety Concerns and the TIOSPIR Study
    • 8.6.4.3 Ben Venue Laboratories Shut Down
    • 8.6.4.4 Sale of Roxane Laboratories
    • 8.6.4.5 Spiloto Respimat and the PHYSACTO Study
• 8.7 AstraZeneca
  • 8.7.1 AstraZeneca: Asthma and COPD Therapies
  • 8.7.2 AstraZeneca: Sales Forecast 2017-2029
  • 8.7.3 AstraZeneca: Products in Development
  • 8.7.4 AstraZeneca: Recent Developments
    • 8.7.4.1 AstraZeneca Acquires Almirall's Respiratory Portfolio
    • 8.7.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca's Combination Drug Pipeline
    • 8.7.4.3 AstraZeneca Rejects Pfizer Takeover Bid
    • 8.7.4.4 AstraZeneca Acquires Right to Actavis' Branded Respiratory Portfolio in US and Canada
    • 8.7.4.5 Takeda Respiratory Portfolio Acquisition
• 8.8 Merck & Co. (Merck)
  • 8.8.1 Merck: Asthma and COPD Therapies
  • 8.8.2 Merck: Sales Forecast 2017-2029
  • 8.8.3 Merck: Products in Development
  • 8.8.4 Merck: Recent Developments
    • 8.8.4.1 Bayer Acquires Merck's Consumer Health Business
    • 8.8.4.2 FDA Rejects Singulair OTC Switch
    • 8.8.4.3 Takeda Ended Co-Promotion of Daxas with Merck
• 8.9 Novartis
  • 8.9.1 Novartis: Asthma and COPD Therapies
  • 8.9.2 Novartis: Sales Forecast 2017-2029
  • 8.9.3 Novartis: Products in Development
  • 8.9.4 Novartis: Recent Developments
    • 8.9.4.1 Novartis Restructures Following Strategic Review
    • 8.9.4.2 Novartis Presents Data on Ultibro and Seebri
    • 8.9.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
• 8.10 Roche
  • 8.10.1 Roche: Asthma and COPD Therapies
  • 8.10.2 Roche: Sales Forecast 2017-2029
  • 8.10.3 Roche: Products in Development
• 8.11 Teva
  • 8.11.1 Teva: Asthma and COPD Therapies
  • 8.11.2 Teva: Sales Forecast 2017-2029
  • 8.11.3 Teva: Products in Development
  • 8.11.4 Teva: Recent Developments
    • 8.11.4.1 Launch of DuoResp Spiromax

9. Asthma and COPD Therapies Pipeline Analysis 2017-2029

• 9.1 A Strong Asthma and COPD Pipeline
• 9.2 The Bronchodilators Pipeline
  • 9.2.1 Bronchodilators: Phase 3 Pipeline
    • 9.2.1.1 AZD8871 (MABA, AstraZeneca)
    • 9.2.1.2 GSK961081 (Batefenterol, GSK)
    • 9.2.1.3 LAS100977 (Abediterol, AstraZeneca)
    • 9.2.1.4 QVAR BAI (beclometasone, Teva)
• 9.3 The Anti-Inflammatory Drugs Pipeline
  • 9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
    • 9.3.1.1 mepolizumab (IL-5 receptor antagonist, GSK)
    • 9.3.1.2 benralizumab (IL-5 receptor antagonist, AstraZeneca)
    • 9.3.1.3 tralokinumab (IL-13 receptor antagonist, AstraZeneca)
    • 9.3.1.4 QAW039 (fevipiprant, Novartis)
    • 9.3.1.5 Lebrikizumab (IL-13 receptor antagonist, Roche)
• 9.4 The Combination Drugs Pipeline
  • 9.4.1 Combination Drugs: Phase 3 Pipeline
    • 9.4.1.1 fluticasone furoate & vilanterol & umeclidinium (GSK)
    • 9.4.1.2 PT010 (long-acting muscarinic antagonist (LAMA) glycopyrronium, the long acting β2-agonist (LABA) formoterol fumarate and budesonide, an inhaled corticosteroid (ICS), AstraZeneca)
    • 9.4.1.3 QMF149 (indacaterol, mometasone furoate, Novartis)
    • 9.4.1.4 QVM149 (indacaterol, glycopyrronium, mometasone, Novartis)
• 9.5 Other Asthma and COPD Drugs Pipeline

10. Qualitative Analysis of the Asthma and COPD Therapies Market 2017-2029

• 10.1 SWOT Analysis of the Asthma and COPD Therapies Market
• 10.2 Strengths
  • 10.2.1 Increasing Prevalence and Disease Burden
  • 10.2.2 High Costs of Treatment
  • 10.2.3 The Changing Perception of COPD
  • 10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
  • 10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
  • 10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
  • 10.2.7 Developments in Diagnostics
    • 10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
    • 10.2.7.2 Biological Markers in COPD
• 10.3 Weaknesses
  • 10.3.1 Under-Diagnosis: the ‘Ghost Population'
  • 10.3.2 Side-Effects of Drug Classes
  • 10.3.3 Patent Cliff for Devices
  • 10.3.4 Low Patient Adherence
  • 10.3.5 Costing Pressures in both Developed and Emerging Markets
• 10.4 Opportunities
  • 10.4.1 Patient Phenotyping and Personalised Medicine
  • 10.4.2 A Strong R&D Pipeline
  • 10.4.3 Ultra-Long-Acting Beta2-Agonists
  • 10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs)
  • 10.4.5 Monoclonal Antibodies
  • 10.4.6 LAMA/LABA Combinations
  • 10.4.7 Opportunities in Telehealth
• 10.5 Threats
  • 10.5.1 Patent Expiry and Generic Competition
  • 10.5.2 Pharmacy Benefit Managers and Cost Control
  • 10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
• 10.6 Porter's Five Forces Analysis of the Asthma and COPD Therapies Market
  • 10.6.1 Rivalry among Competitors [Medium]
  • 10.6.2 Threat of New Entrants [Medium]
  • 10.6.3 Power of Suppliers [Medium]
  • 10.6.4 Power of Buyers [High]
  • 10.6.5 Threat of Substitutes [Low]

11. Conclusions

• 11.1 Asthma and COPD Therapies: A Maturing Market
• 11.2 The Global Asthma and COPD Therapies Market in 2017
• 11.3 Current Leading Asthma and COPD Therapies Segments
  • 11.3.1 Leading Asthma and COPD Therapies
  • 11.3.2 Leading Asthma and COPD Therapies Companies
• 11.4 Leading Regional and National Markets
• 11.5 Global Asthma and COPD Therapies Market Forecast 2017-2029
• 11.6 The Future of the Asthma and COPD Therapies Market
  • 11.6.1 Growth in Anti-Inflammatory and Combination Drugs
  • 11.6.2 Personalised Medicine
  • 11.6.3 Unmet Needs in Asthma and COPD
• 11.7 Strategies for Growth in 2017-2029

Appendices

• Associated Visiongain Reports
• Visiongain Report Sales Order Form
• Appendix A
• About Visiongain
• Appendix B
• Visiongain report evaluation form